Phenocopy – A Strategy to Qualify Chemical Compounds during Hit-to-Lead and/or Lead Optimization

A phenocopy is defined as an environmentally induced phenotype of one individual which is identical to the genotype-determined phenotype of another individual. The phenocopy phenomenon has been translated to the drug discovery process as phenotypes produced by the treatment of biological systems with new chemical entities (NCE) may resemble environmentally induced phenotypic modifications. Various new chemical entities exerting inhibition of the kinase activity of Transforming Growth Factor β Receptor I (TGF-βR1) were qualified by high-throughput RNA expression profiling. This chemical genomics approach resulted in a precise time-dependent insight to the TGF-β biology and allowed furthermore a comprehensive analysis of each NCE's off-target effects. The evaluation of off-target effects by the phenocopy approach allows a more accurate and integrated view on optimized compounds, supplementing classical biological evaluation parameters such as potency and selectivity. It has therefore the potential to become a novel method for ranking compounds during various drug discovery phases.

[1]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[2]  M. Damha,et al.  Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid (FANA) , 2006, Nucleic acids research.

[3]  S. Akira,et al.  Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides , 2006, European journal of immunology.

[4]  Walter A. Korfmacher,et al.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034 , 2007, Perspectives in medicinal chemistry.

[5]  A. Klippel,et al.  Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. , 2003, Nucleic acids research.

[6]  S. Kloeker,et al.  TGF-beta inhibitors for the treatment of cancer. , 2005, Expert opinion on investigational drugs.

[7]  Dana M. Brantley-Sieders,et al.  Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.

[8]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[9]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[10]  Stephen H. Friend,et al.  Toxicogenomics and drug discovery: will new technologies help us produce better drugs? , 2002, Nature Reviews Drug Discovery.

[11]  D. Boschelli,et al.  2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. , 1998, Journal of medicinal chemistry.

[12]  U. Kristen,et al.  In vitro cytotoxicity testing for prediction of acute human toxicity , 1994, Cell Biology and Toxicology.

[13]  D. Gerhold,et al.  Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. , 2001, Physiological genomics.

[14]  A. Chetta,et al.  Review: Therapeutic perspectives in bronchial vascular remodeling in COPD , 2008, Therapeutic advances in respiratory disease.

[15]  S. Kloeker,et al.  TGF-β inhibitors for the treatment of cancer , 2005 .

[16]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[17]  I. M. Wormstone,et al.  Oligonucleotide microarray analysis of human lens epithelial cells: TGFbeta regulated gene expression. , 2007, Molecular vision.

[18]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[19]  B. Ozdamar.  Receptors Controls Epithelial Cell Plasticity Regulation of the Polarity Protein Par6 by TGFß , 2007 .

[20]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[21]  Jun Zou,et al.  Microarray profile of differentially expressed genes in a monkey model of allergic asthma , 2002, Genome Biology.

[22]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[23]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[24]  Philippe Rigault,et al.  A novel, high-performance random array platform for quantitative gene expression profiling. , 2004, Genome research.

[25]  Stefano Piccolo,et al.  Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. , 2007, Science.

[26]  A. Klippel,et al.  Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. , 2003, Oncogene.

[27]  Robert Langer,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[28]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[30]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[31]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[32]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[33]  J. Brugge,et al.  ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression? , 2004, Cell cycle.

[34]  D. Lockhart,et al.  Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.

[35]  C. Brinckerhoff,et al.  Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors , 2001, Arthritis Research & Therapy.

[36]  L. J. Eldik,et al.  Targeting protein kinases in central nervous system disorders , 2009, Nature Reviews Drug Discovery.

[37]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[38]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[39]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[40]  A. D. Rodrigues,et al.  Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. , 2002, Current drug metabolism.

[41]  C. Echeverri,et al.  Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. , 2008, Cell host & microbe.

[42]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[43]  Ravi Kiran Reddy Kalathur,et al.  Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells , 2007, BMC Genomics.

[44]  Mark W. Craven,et al.  Identification of toxicologically predictive gene sets using cDNA microarrays. , 2001, Molecular pharmacology.

[45]  Michael Karin,et al.  Intracellular pattern recognition receptors in the host response , 2006, Nature.

[46]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[47]  J. Wrana,et al.  Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. , 2003, Nature cell biology.

[48]  J. Han,et al.  Distinct regulation of gene expression in human endothelial cells by TGF-beta and its receptors. , 2006, Microvascular research.

[49]  S. Frantz.  Drug discovery: Playing dirty , 2005, Nature.

[50]  J. Yingling,et al.  Development of TGF-beta signalling inhibitors for cancer therapy. , 2004, Nature reviews. Drug discovery.

[51]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[52]  A. Klippel,et al.  Differential regulation of TGF-β signaling through Smad2, Smad3 and Smad4 , 2003, Oncogene.

[53]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[54]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[55]  Tin Oo Khor,et al.  Toxicogenomics in Drug Discovery and Drug Development: Potential Applications and Future Challenges , 2006, Pharmaceutical Research.

[56]  Anastasia Khvorova,et al.  Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.

[57]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[58]  K. Kelnar,et al.  High-throughput RNAi screening in vitro: from cell lines to primary cells. , 2005, RNA.

[59]  Lincoln Stein,et al.  Reactome knowledgebase of human biological pathways and processes , 2008, Nucleic Acids Res..

[60]  Phillip D Zamore,et al.  Perspective: machines for RNAi. , 2005, Genes & development.

[61]  Paul Martin,et al.  Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration , 2006, Journal of Cell Science.

[62]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[63]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Lehmann,et al.  Targeted mRNA degradation by double-stranded RNA in vitro. , 1999, Genes & development.

[65]  C. Joo,et al.  Rho plays a key role in TGF‐β1‐induced cytoskeletal rearrangement in human retinal pigment epithelium , 2008, Journal of cellular physiology.

[66]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[67]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[68]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[69]  E. Hovig,et al.  Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. , 2007, Journal of molecular biology.

[70]  R. Ulrich,et al.  Profiling of hepatic gene expression in rats treated with fibric acid analogs. , 2004, Mutation research.

[71]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[72]  J. Ernst,et al.  A fluorometric assay for the quantification of RNA in solution with nanogram sensitivity. , 1995, Analytical biochemistry.

[73]  A. Schulze,et al.  Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. , 2000, Genes & development.

[74]  L. Nádasdi,et al.  Linking Solubility and Permeability Assays for Maximum Throughput and Reproducibility , 2005, Journal of biomolecular screening.

[75]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[76]  M. Chanson,et al.  Gap junctional communication in tissue inflammation and repair. , 2005, Biochimica et biophysica acta.

[77]  R. Heller,et al.  Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. , 1997, Critical reviews in eukaryotic gene expression.

[78]  W. Huber,et al.  Model-based variance-stabilizing transformation for Illumina microarray data , 2008, Nucleic acids research.

[79]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[80]  R. Eils,et al.  Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3 , 2010, BMC Genomics.

[81]  Ziv Shkedy,et al.  Testing for Trends in Dose-Response Microarray Experiments: A Comparison of Several Testing Procedures, Multiplicity and Resampling-Based Inference , 2007, Statistical applications in genetics and molecular biology.

[82]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[83]  Jian Cao,et al.  Transcriptional Profiling of the Dose Response: A More Powerful Approach for Characterizing Drug Activities , 2009, PLoS Comput. Biol..

[84]  Fang Liu,et al.  Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. , 2005, Biochemistry.

[85]  F. Crick,et al.  The structure of DNA. , 1953, Cold Spring Harbor symposia on quantitative biology.

[86]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[87]  Kai Wang,et al.  Comparative analysis of microarray normalization procedures: effects on reverse engineering gene networks , 2007, ISMB/ECCB.

[88]  D. Schöevaërt,et al.  TGF beta 1 promotes actin cytoskeleton reorganization and migratory phenotype in epithelial tracheal cells in primary culture. , 1996, Journal of cell science.

[89]  G. Rudkin,et al.  Transforming growth factor-beta, osteogenin, and bone morphogenetic protein-2 inhibit intercellular communication and alter cell proliferation in MC3T3-E1 cells. , 1996, Journal of cellular physiology.

[90]  M. King,et al.  BRCA1 transcriptionally regulates genes involved in breast tumorigenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[92]  R. Homer,et al.  Transforming Growth Factor (TGF)-β1 Stimulates Pulmonary Fibrosis and Inflammation via a Bax-dependent, Bid-activated Pathway That Involves Matrix Metalloproteinase-12* , 2007, Journal of Biological Chemistry.

[93]  B. Aggarwal,et al.  Melanoma Differentiation-Associated Gene-7/IL-24 Gene Enhances NF-κB Activation and Suppresses Apoptosis Induced by TNF , 2004, The Journal of Immunology.

[94]  Ian Walker,et al.  Do molecularly targeted agents in oncology have reduced attrition rates? , 2009, Nature Reviews Drug Discovery.

[95]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[96]  Yudong D. He,et al.  Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.

[97]  Grant W. Brown,et al.  Chemical–Genetic Profiling of Imidazo[1,2-a]pyridines and -Pyrimidines Reveals Target Pathways Conserved between Yeast and Human Cells , 2008, PLoS genetics.

[98]  S. Dupont,et al.  Links between Tumor Suppressors p53 Is Required for TGF-β Gene Responses by Cooperating with Smads , 2003, Cell.

[99]  Yongliang Yang,et al.  Target discovery from data mining approaches. , 2009, Drug discovery today.

[100]  B. Sönnichsen,et al.  Divalent Rab effectors regulate the sub-compartmental organization and sorting of early endosomes , 2002, Nature Cell Biology.

[101]  T. Speed,et al.  Statistical issues in cDNA microarray data analysis. , 2003, Methods in molecular biology.

[102]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[103]  G J Roth,et al.  Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis , 2007, European Respiratory Journal.

[104]  B. Williams,et al.  RNA interference and double-stranded-RNA-activated pathways. , 2004, Biochemical Society transactions.

[105]  Xiao-Fan Wang,et al.  Signaling cross-talk between TGF-β/BMP and other pathways , 2009, Cell Research.

[106]  J. Downward,et al.  Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. , 2002, The Journal of cell biology.

[107]  T. Nakagami,et al.  Cx43 mediates TGF-beta signaling through competitive Smads binding to microtubules. , 2007, Molecular biology of the cell.

[108]  D. Mennerich,et al.  Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI). , 2010, Journal of medicinal chemistry.

[109]  C. Arteaga,et al.  Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility* , 2004, Journal of Biological Chemistry.

[110]  Ragu Ramanathan,et al.  Mass spectrometry in drug metabolism and pharmacokinetics , 2008 .

[111]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[112]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[113]  C. Heldin,et al.  Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation. , 2001, American journal of respiratory cell and molecular biology.

[114]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[115]  S. Byers,et al.  The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. , 2005, Oncogene.

[116]  K. M. Mulder,et al.  Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. , 2000, The Journal of biological chemistry.

[117]  Lee Bennett,et al.  Prediction of compound signature using high density gene expression profiling. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[118]  Anastasia Khvorova,et al.  Experimental validation of the importance of seed complement frequency to siRNA specificity. , 2008, RNA.

[119]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[120]  Javier Martinez,et al.  hClp1, A Novel Kinase Revitalizes RNA Metabolism , 2007, Cell cycle.

[121]  E. Ho,et al.  Measurements of drug-protein binding by using immobilized human serum albumin liquid chromatography-mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[122]  J. Kjems,et al.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity , 2009, Nucleic acids research.

[123]  S. Steinberg,et al.  Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. , 2007, Molecular interventions.

[124]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[125]  A. Schmidt,et al.  The regulatory domain of the RIG-I family ATPase LGP2 senses double-stranded RNA , 2009, Nucleic acids research.

[126]  C. Echeverri,et al.  LNA incorporated siRNAs exhibit lower off-target effects compared to 2'-OMethoxy in cell phenotypic assays and microarray analysis. , 2008, Nucleic acids symposium series.

[127]  J J Chen,et al.  Selection of differentially expressed genes in microarray data analysis , 2007, The Pharmacogenomics Journal.

[128]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[129]  P. Zamore,et al.  ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway , 2001, Cell.

[130]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[131]  Simon K. Mencher,et al.  BMC Clinical Pharmacology BioMed Central Debate , 2005 .

[132]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[133]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[134]  P. Higgins,et al.  Regulation of Extracellular Matrix Remodeling following Transforming Growth Factor-β1/Epidermal Growth Factor-Stimulated Epithelial-Mesenchymal Transition in Human Premalignant Keratinocytes , 2007, Cells Tissues Organs.

[135]  Monika Milewski,et al.  Decoding randomly ordered DNA arrays. , 2004, Genome research.

[136]  Connie R Jimenez,et al.  Proteomics strategies for target identification and biomarker discovery in cancer. , 2009, Frontiers in bioscience.

[137]  Ralf J. Sommer,et al.  The evolution of signalling pathways in animal development , 2003, Nature Reviews Genetics.

[138]  F. Hilberg,et al.  Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). , 2009, Journal of medicinal chemistry.

[139]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[140]  T. Aigner,et al.  TAK1 downregulation reduces IL-1beta induced expression of MMP13, MMP1 and TNF-alpha. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[141]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[142]  A. Judge,et al.  Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.

[143]  J. Hornung,et al.  Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line , 1988, The Journal of cell biology.

[144]  J. Watelet,et al.  Drug metabolism and pharmacokinetics , 2009, Drug metabolism reviews.

[145]  Anita B. Roberts,et al.  Role of Rho/ROCK and p38 MAP Kinase Pathways in Transforming Growth Factor-β-mediated Smad-dependent Growth Inhibition of Human Breast Carcinoma Cells in Vivo* , 2004, Journal of Biological Chemistry.

[146]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[147]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[148]  Kim L R Brouwer,et al.  Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[149]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[150]  W. Gerald,et al.  The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin , 1999, Cell.